MedTrace Logo

Endermologie Versus Negative Pressure Therapy on Postmastectomy Lymphedema

NCT05761353 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2023-12-27

No results posted yet for this study

Summary

Statement of the problem:

The problem will be stated in a questionary form:

"Which will be more effective endermologie or negative pressure therapy in reducing limb circumference and volume in postmastectomy lymphedema?".

Hypothesis:

It will be hypothesized that:

There is no significant difference between endermologie and negative pressure therapy in reducing circumference and limb volume in post mastectomy lymphedema.

Conditions

  • Mastectomy; Lymphedema

Interventions

DEVICE

Endermologie

Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks. Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand. -In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

DEVICE

Negative pressure therapy

Group B will receive negative pressure therapy with * Pressure: 20-250 mmHg. * Total treatment period: 6weeks * A number of sessions: 3sessions/ week. Time of application : 30 min * In addition to physical therapy program (active range of motion and elevation); hygiene and skin care

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Rayda M Mohamed · Cairo Unversity

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-29
Primary Completion
2023-06-01
Completion
2023-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05761353 on ClinicalTrials.gov